Sandu Pharmaceuticals Limited

As of June 30, 2026, Sandu Pharmaceuticals Limited carries a market capitalization of 396.10M, placing it among publicly traded companies globally. Its enterprise value stands at 396.10M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Sandu Pharmaceuticals Limited has 9.66M shares outstanding.

As of June 30, 2026, Sandu Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 23.08.

As of June 30, 2026, Sandu Pharmaceuticals Limited trades at an EV/EBITDA multiple of 13.15 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.87 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 396.10M versus a market cap of 396.10M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 2.48M in revenue per employee across its workforce of 280.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Sandu Pharmaceuticals Limited recorded 9.06M in income tax expense. That works out to an effective tax rate of 33.89, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 26.74M, leaving 17.71M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Sandu Pharmaceuticals Limited's stock has declined approximately 25.66% over the past 52 weeks. The 50-day moving average sits at 37.02, while the 200-day moving average is 38.05.

Over the twelve months ended June 30, 2026, Sandu Pharmaceuticals Limited generated 696.24M in revenue and converted that into 17.71M in net income, yielding earnings per share of 1.78. EBITDA reached 30.12M, while operating income came in at 23.49M.

Over the twelve months ended June 30, 2026, Sandu Pharmaceuticals Limited posted a gross margin of 57.95, reflecting its pricing power and cost economics. The operating margin of 3.37 and net profit margin of 2.54 provide insight into operational efficiency.